What's Happening?
Katherine Szarama has been appointed as the acting director of the FDA's Center for Biologics Evaluation and Research (CBER), following the end of Vinay Prasad's tumultuous tenure. Szarama, who previously served as Prasad's deputy, steps into the role
as the FDA navigates leadership transitions. Prasad's tenure was marked by controversy, including the handling of Sarepta Therapeutics' gene therapy issues.
Why It's Important?
The appointment of Szarama as acting director comes at a critical time for the FDA, as it continues to address challenges in the regulation of biologics and gene therapies. Leadership stability is crucial for maintaining public trust and ensuring effective oversight of medical products. Szarama's background in biophysics and her experience within the FDA position her to guide the division through ongoing regulatory and scientific developments. Her leadership will be pivotal in shaping the future direction of the CBER.
